← board
INM
distress 6/10 · elevated risk$1.660%today-48% from 52w high
Lead: Alzheimer's disease · est. market ~$8B (approx, global)
Revenue
pre-revenue
Liquidity
$5M
Runway
0.6 yrs
Shares 1y
+39%
Price & events
+55.1% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
+4.4%
1W
+10.7%
1M
+117.8%
3M
+49.5%
6M
-38.3%
1Y
-67.8%
2Y
-99.9%
5Y
-99.9%
All
Overview
- Market Cap
- $5.50M
- Volume
- 434.47K
- 52 Week Range
- $0.61 – $3.17
- Total Shares
- 3.31M
- Float Shares
- 767.44K
- Short %
- 2.67%
- % Held by Insiders
- 0.12%
- % Held by Institutions
- 69.87%
- RVOL
- 0.24x
- Beta
- 0.95
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 5
- 2026-09-23earningsEarningsEarnings releaseyahoo
- 2026-05-19partnershipEntered into merger agreement with Mentari Therapeutics, with pre-closing financing of at least $150M.SEC 8-K
- 2026-05-18partnershipAmended exercise price of preferred investment options from $16.60 to $0.80.SEC 8-K
- 2026-03-04withdrawalWind down of BayMedica commercial operations due to H.R. 5371 impact; expected to complete by June 30, 2026.SEC 8-K
- July 27–31, 2025conferencedata presentationsecondaryINM-901 · Presenting new preclinical data at AAIC 2025SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors — Alzheimer's disease
- BMYBRISTOL MYERS SQUIBB CO$124.5B · D0
- AXSMAxsome Therapeutics, Inc.$12.3B · D0
- ACADACADIA PHARMACEUTICALS INC$4.2B · D0
- DNLIDenali Therapeutics Inc.$3.6B · D2
- NAMSNewAmsterdam Pharma Co N.V.$3.6B · D0
- MPLTMapLight Therapeutics, Inc.$1.5B · D2
- NMRANeumora Therapeutics, Inc.$281M · D5
- PMNProMIS Neurosciences Inc.$125M · D5
- ANVSAnnovis Bio, Inc.$59M · D8
- INMBInmune Bio, Inc.$47M · D5
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.